Sandro Nalli, PhD

Atrium Therapeutics における SVP, Technical Operations

スピーカー

Sandro Nalli is Senior Vice President, Technical Operations at Atrium Therapeutics, leading Technical Development, Analytical Development and Quality Control, Quality Assurance, Manufacturing, CMC strategy, and supply chain for Atrium's targeted RNA delivery platform for rare genetic cardiomyopathies. He joined in April 2026 as part of Atrium's spinout from Avidity Biosciences. Sandro brings more than 20 years of CMC and technical operations leadership across biologics, oligonucleotides, ADCs, and small molecules. He previously spent nearly four years at Avidity Biosciences as Vice President, Technical Development, leading a 40-plus-person team across the AOC pipeline and authoring the company's first BLA submission. Earlier roles include Strategy and Operations Lead at Spark Therapeutics, Director of CMC Management & Operations and Global CMC Lead for ENHERTU at Daiichi Sankyo, and nine years at GSK spanning bioprocess development, CMO/CRO outsourcing, and CMC portfolio management.